HCA (HCA) Q3 2026 Earnings Call Transcript

HCA Healthcare reported Q3 2026 revenue of $19.849B, up 3.6% year over year, and adjusted diluted EPS of $7.22, up 3.7%; management said full-year 2026 revenue and adjusted EBITDA should land in the upper half of their guidance ranges. Equivalent admissions grew 3%, but a shift from exchange-covered to uninsured patients reduced adjusted EBITDA by about $400M in the quarter, while net income fell to $1.579B from $1.643B. Management expects 2027 earnings to be generally consistent with 2026 and $550M–$650M less in Medicaid supplemental-payment net benefits; HCA repurchased $2.970B of shares in Q3.

Analysis

The key issue is earnings quality, not volume: patients migrating from exchange coverage to uninsured status can preserve admissions while reducing realized revenue and collection. That makes headline volume resilience a weaker read-through to cash earnings than in a normal demand cycle. The preliminary 2027 flat-EBITDA view, despite 2–3% volume growth, implies that operating leverage and cost actions are initially absorbing—not eliminating—the combined payer-mix and supplemental-payment drag. Buybacks may support EPS optics, but should not be mistaken for underlying EBITDA growth.

Near term, the next meaningful information set is exchange enrollment through January and HCA’s full-year 2027 guidance. Sequential exchange-volume improvement is encouraging but does not resolve whether uninsured share has peaked. Over 6–18 months, inpatient capacity constraints could support growth, while elective softness and rising radiology/anesthesia fees limit conversion of volume into margin. The proposed 340B-related OPPS change is optional upside only: its final terms and any legal challenge matter, and the company has not sized the benefit.

The contrarian risk is that investors treat strong admissions and cost discipline as proof the payer shock is transient. If coverage losses persist, admissions can stay healthy while reimbursement quality deteriorates; HR 1 work requirements add another, though still uncertain, source of Medicaid mix pressure. Conversely, a stable uninsured share plus sustained per-admission cost control would make the current flat-earnings outlook conservative. No valuation or price data are supplied, so a directional entry level cannot be justified here.

Key Decisions for Investors

• No immediate directional trade in HCA on this information alone. Keep exposure at benchmark weight pending the January outlook; the operating signal is mixed and no valuation or post-call price reaction is provided.
• Set an add-on-weakness alert for HCA, conditional on exchange enrollment and uninsured equivalent-admission share stabilizing, while cost per equivalent admission remains controlled. That would support the case that volume growth can eventually translate into earnings growth.
• Reduce or hedge HCA exposure if uninsured share continues rising or management’s January outlook implies further deterioration in core EBITDA before supplemental payments. Track elective procedure volumes and radiology/anesthesia costs as leading indicators of margin conversion.
• Treat the proposed 340B/OPPS change as a catalyst watch, not base-case earnings: verify final CMS language, timing, and any litigation before assigning value to the potential benefit.